Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04903873
Other study ID # EU-CTS101-I-01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 31, 2021
Est. completion date December 2025

Study information

Verified date March 2024
Source Eutilex
Contact Seoyoun Kim, MPH
Phone 82-10-4227-0925
Email s.kim@eutilex.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date December 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed because of disease progression or unacceptable toxicities. Also includes patients who cannot be treated with standard therapy because of underlying/existing medical condition. - Cohort 1 (colorectal cancer): a) CRC (including microsatellite instability-high [MSI-H] and microsatellite-stable [MSS]) regardless of RAS mutation. b) Disease progression within 3 months after last administration of approved standard therapies. c) Prior cytotoxic chemotherapy for metastatic disease include all the following agents: fluoropyrimidine, oxaliplatin, and irinotecan - Adjuvant chemotherapy-based treatments count as prior therapy, as long as relapse had occurred within 6 months of completion of such therapies, prior anti-epidermal growth factor receptor (EGFR) therapy (cetuximab, panitumumab), anti-angiogenic therapy (bevacizumab, aflibercept, ramucirumab), regorafenib, and TAS-102 are allowed. d) No more than 5 prior therapies for metastatic disease. For participants who had disease recurrence within 6 months of completing adjuvant chemotherapy, the adjuvant regimen can be considered as 1 chemotherapy regimen for metastatic disease - Cohort 2 (NSCLC): a) NSCLC without known EGFR, anaplastic lymphoma kinase (ALK), and ROS1 genomic tumor aberrations. b) No standard therapy exists or standard therapy has failed. c) No more than 3 prior therapies for metastatic disease - Phase 2: At least 1 measurable lesion per RECIST version 1.1 - Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 - Adequate organ and bone marrow function (Hemoglobin >9.0 g/dL, Absolute neutrophil count =1,500/µL, Absolute lymphocyte count =600 and =2,500/µL, Platelet count =100,000/µL, Total bilirubin =1.5 × upper limit of normal, Alanine aminotransferase and aspartate aminotransferase =2.5 × ULN, Serum creatinine =1.5 × ULN or creatinine clearance >30 mL/min, Prothrombin time and activated partial thromboplastin time =1.5 × ULN) - Life expectancy of at least 12 weeks - Voluntarily provided a written consent to participate in the study - Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days before study drug administration - WOCBP and sexually active fertile male patients with partners who are WOCBP must agree to use 2 highly effective methods of contraception throughout the course of the study and for 12 weeks after the last dose of study drug. Key Exclusion Criteria: - Primary central nervous system (CNS) tumor (Phase 1), CNS metastasis, and/or carcinomatous meningitis. Participants with prior brain metastases treated at least 4 weeks before the first dose of EU101 that are clinically stable and do not require chronic corticosteroid treatment are allowed. Untreated but asymptomatic and clinically stable brain metastases per investigator's discretion are allowed - Received prior therapy with any anti-CD137 monoclonal antibody (mAb) or agent - Major surgery requiring general anesthesia within 3 weeks before first dose of EU101 or still recovering from prior surgery - Active infection that is not controlled or requires intravenous antibiotics in the last 2 weeks - History of allogeneic tissue or organ transplant - Active hepatitis B virus or hepatitis C virus infection - History of any noninfectious hepatitis - Human immunodeficiency virus (HIV) infection - Received or receiving systemic corticosteroid therapy or any other form of systemic immunosuppressive medicaion 1 week before first dose of EU101 - Known severe (=Grade 3) hypersensitivity reactions to antibody, or severe reaction to immuno-oncology agents requiring treatment with steroids - Konwn or suspected hypersensitivity to EU101 or any component of its formulation - Current or history of interstitial lung disease, anaphylaxis, uncontrolled asthma, or pneumonitis that has required systemic corticosteroids - Patients with second primary cancer - Clinically significant concurrent cardiovascular disease - Pregnant women, breasfeeding women, WOCBP, or men with partners who are WOCBP who do not agree to use adequate contraceptive measures - Determined as unable to participate in the study per investigator's judgment Other protocol defined Inclusion/Exclusion criteria may apply

Study Design


Intervention

Drug:
EU101
EU101 will be administered via intravenous infusion.

Locations

Country Name City State
Korea, Republic of National Cancer Center Ilsan
Korea, Republic of Samsung Seoul Hospital Seoul
Korea, Republic of Seoul Asan Seoul
Korea, Republic of Severance Hospital Seoul
United States Mary Crowley Center Dallas Texas
United States Fox Chase Cancer Center Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Eutilex

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1: Number of Participants With Adverse Event (AEs) and Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation Baseline up to 30 months
Primary Phase 1: Number of Participants With Dose Limiting Toxicity (DLT) At the end of Cycle 1 (Each cycle is of 21 Days)
Primary Phase 1: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Laboratory assessments include hematology, serum chemistry, other blood tests, coagulation, and urine analysis. Number of participants with clinically significant abnormalities will be reported. Baseline up to 24 months
Primary Phase 1: Number of Participants With Clinically Significant Abnormalities in Vital Signs Vital signs will include body temperature, pulse rate, and systolic and diastolic blood pressure measurements. Number of participants with clinically significant abnormalities will be reported. Baseline up to 24 months
Primary Phase 1: Number of Participants With Clinically Significant Abnormalities in Physical Examination Physical examination will include head, eyes, ears, nose and throat; heart; lungs; abdomen; skin; cervical and axillary lymph nodes; and neurological and musculoskeletal systems. Number of participants with clinically significant abnormalities will be reported. Baseline up to 24 months
Primary Phase 1: Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) ECG parameters included heart rhythm, pulse rate intervals, QRS, QT intervals, RR intervals and corrected QT(QTc) intervals. Number of participants with clinically significant abnormalities will be reported. Baseline up to 24 months
Primary Phase 2: Objective Response Rate (ORR) Objective response rate (ORR), defined as the percentage of participants with a best overall response (BOR) of either a complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors by investigators. Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)
Secondary Phase 1: Objective Response Rate (ORR) Objective response rate (ORR), defined as the percentage of participants with a BOR of either a complete response (CR) or partial response (PR), per RECIST version 1.1 for solid tumors by investigators. Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 24 months)
Secondary Phase 1 and 2: Duration of Response (DOR) Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Disease Control Rate (DCR) DCR will be defined similarly to ORR but also including stable disease (SD) in the categorization of response (i.e, RECIST response of either CR, PR, or SD). Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Time to Response (TTR) Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Time to Progression (TTP) Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Durable Clinical Benefit (DCB) DCB will be defined similarly to DCR but additionally specifying that the disease control be achieved for at least 12 weeks consecutive (i.e, RECIST response of CR, PR or SD for greater than or equal to [>=] 12 weeks consecutive). Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Progression-Free Survival (PFS) Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Overall survival (OS) Time from first dose of study treatment assessed until disease progression, death, withdrawal of consent, physician's decision, start of new anticancer therapy, or end of study, whichever occurs first (approximately for 56 months)
Secondary Phase 1 and 2: Maximum Observed Serum Concentration (Cmax) of EU101 Cmax is defined as maximum observed serum concentration. Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Trough Serum Concentration (Ctrough) of EU101 Ctrough is steady-state pre-dose concentration. Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of EU101 Tmax is defined as time to reach maximum observed serum concentration. Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours Post-dose (AUC0-24) of EU101 AUC0-24 is defined as the area under the serum concentration versus time curve from time zero (pre-dose) to 24 hours post-dose (0 to 24). Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Area Under the Serum Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of EU101 AUC0-last is defined as area under the serum concentration time-curve from time zero to the time of last measured concentration. Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Area Under the Serum Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of EU101 AUCinf is defined as area under the serum concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Elimination Half-Life Time (T1/2) of EU101 T1/2 is defined as plasma decay half-life is the time measured for the serum concentration to decrease by one half. Cycle 1: Pre-dose up to 336 hours post-dose; Cycle 2: 504 hours post-dose; Cycle 3: Pre-dose (Each cycle is of 21 days)]
Secondary Phase 1 and 2: Apparent Volume of Distribution (Vd/F) of EU101 Vd/F is defined as volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Baseline (Day 1)
Secondary Phase 1 and 2: Apparent Oral Clearance of (CL/F) of EU101 Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Baseline (Day 1)
Secondary Phase 1 and 2: Mean Residence Time (MRT) of EU101 MRT is defined as AUMC(0 - inf) divided by AUC(0 - inf), where AUMC(0 - inf) is the area under the first moment curve from time 0 extrapolated to infinite time. Baseline (Day 1)
Secondary Phase 1 and 2: Renal clearance (CLr) of EU101 CLr is defined as renal clearance is the volume of plasma completely cleared of EU101 by the kidneys per unit time. Baseline (Day 1)
Secondary Phase 1 and 2: Number of Participants with Positive Antidrug Antibodies (ADA) The immunogenic potential of EU101 will be assessed by summarizing the number of participants who develop detectable antidrug antibody (ADAs). Baseline up to 56 months
Secondary Phase 2: Number of Participants With AEs and SAEs by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Time from first dose of study treatment up to 30 months
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A